Product Information
ALOGLIPTIN 6.25 MG TABLET is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $5.2782 per EA under NDC 45802008765. Its NADAC has been published 463 times since Apr 19, 2017.
FDA first approved this application on Jan 25, 2013.
Strength
6.25 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802008765
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ALOGLIPTIN BENZOATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA022271FDA Approved
1/25/2013
On Market Since
4/8/2016
Pharmacological Classes
Price Statistics
The NADAC for ALOGLIPTIN 6.25 MG TABLET has been published 463 times since Apr 19, 2017, and over the history we have for it it has declined 5.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.2782 per EA |
|---|---|
| All-time high | $6.2630 (Nov 14, 2018) |
| All-time low | $4.7659 (May 22, 2024) |
| 52-week high | $5.2782 |
| 52-week low | $4.8331 |
| Median price | $5.3837 |
| Average price | $5.3570 |
| Largest weekly change | +16.2% (Oct 21, 2020) |
| Weeks tracked | 463 |
| Tracking since | Apr 19, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Alogliptin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Alogliptin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALOGLIPTIN 6.25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ALOGLIPTIN 6.25 MG TABLET, manufactured by Padagis Israel Pharmaceuticals Ltd, is $5.2782 per EA (NDC 45802008765), effective Sep 30, 2026.
How has the price of ALOGLIPTIN 6.25 MG TABLET changed over time?
Over the history we have for it, the NADAC for ALOGLIPTIN 6.25 MG TABLET has declined 5.9%. It has been tracked across 463 weekly CMS publications since Apr 19, 2017.
What are the highest and lowest recorded NADAC prices for ALOGLIPTIN 6.25 MG TABLET?
Since Apr 19, 2017, the NADAC for ALOGLIPTIN 6.25 MG TABLET has ranged from a low of $4.7659 (May 22, 2024) to a high of $6.2630 (Nov 14, 2018), with a median of $5.3837 per EA.
Are there cheaper alternatives to ALOGLIPTIN 6.25 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ALOGLIPTIN 6.25 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ALOGLIPTIN 6.25 MG TABLET?
ALOGLIPTIN 6.25 MG TABLET (NDC 45802008765) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.